Filing Flows › Humacyte (HUMA) › Q2 2026 › vs Q2 2025
Humacyte (HUMA) Q2 2026 vs Q2 2025 (year over year)
Humacyte's revenue rose $105K (+35%) from $301K in Q2 2025 to $406K in Q2 2026.
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $406K | $301K | $105K | +35% |
| Net loss | $36.8M | $37.7M | −$856K | -2% |
| Costs & expenses | $37.2M | $38.0M | −$751K | -2% |
| Operating costs | $27.4M | $30.0M | −$2.6M | -9% |
| Interest & other, net | $9.8M | $7.9M | $1.9M | +24% |
| Cost of revenue | $1.2M | $213K | $1.0M | +478% |
| Research & development | $18.1M | $22.0M | −$3.9M | -18% |
| Operating cash sources | $36.8M | $37.7M | −$856K | -2% |
| Depreciation | $1.3M | $1.3M | $37K | +3% |
| Share-based compensation | $2.6M | $2.3M | $273K | +12% |
| Working capital & other | $10.8M | $7.6M | $3.2M | +42% |
| Cash used in operations | $22.1M | $26.4M | −$4.4M | -16% |
| Net loss absorbed | $36.8M | $37.7M | −$856K | -2% |
Questions
How much did Humacyte's revenue grow year over year in Q2 2026?
Humacyte's revenue rose $105K (+35%) from $301K in Q2 2025 to $406K in Q2 2026.